ADAR1 Capital Management LLC Buys Shares of 42,821 Dyne Therapeutics, Inc. $DYN

Key Points

• ADAR1 Capital Management initiated a position in Dyne Therapeutics by purchasing 42,821 shares valued at approximately $951,000. Institutional investors collectively own 96.68% of the company.
• Dyne insiders sold substantial stock recently, including director Jason P. Rhodes’ sale of 2.16 million shares for roughly $54 million; insiders sold $99.45 million of shares in total during the last quarter.
• Analysts maintain a generally positive outlook, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $34.42 versus its reported price of $26.34. Dyne missed quarterly EPS estimates, reporting a loss of $1.08 per share versus the expected $0.75 loss.

ADAR1 Capital Management LLC bought a new position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 42,821 shares of the company's stock, valued at approximately $951,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Hilton Head Capital Partners LLC acquired a new position in shares of Dyne Therapeutics during the 1st quarter worth approximately $26,000. Strs Ohio acquired a new stake in Dyne Therapeutics during the 4th quarter valued at $51,000. Allworth Financial LP purchased a new position in Dyne Therapeutics during the second quarter worth $62,000. Aster Capital Management DIFC Ltd purchased a new position in Dyne Therapeutics during the fourth quarter worth $84,000. Finally, Steward Partners Investment Advisory LLC raised its holdings in shares of Dyne Therapeutics by 102.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company's stock worth $95,000 after acquiring an additional 2,465 shares during the last quarter. Hedge funds and other institutional investors own 96.68% of the company's stock.

Insider Transactions at Dyne Therapeutics

In related news, CFO Erick Lucera sold 2,362 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $20.37, for a total transaction of $48,113.94. Following the completion of the sale, the chief financial officer owned 121,563 shares of the company's stock, valued at approximately $2,476,238.31. This represents a 1.91% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jason P. Rhodes sold 2,160,516 shares of the stock in a transaction on Friday, August 14th. The stock was sold at an average price of $25.00, for a total transaction of $54,012,900.00. Following the completion of the sale, the director directly owned 428,946 shares of the company's stock, valued at $10,723,650. The trade was a 83.43% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 4,139,196 shares of company stock valued at $99,449,852 in the last quarter. Company insiders own 9.46% of the company's stock.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Royal Bank Of Canada upped their price objective on Dyne Therapeutics from $30.00 to $35.00 and gave the company an "outperform" rating in a research report on Thursday, July 30th. Cantor Fitzgerald initiated coverage on Dyne Therapeutics in a research report on Thursday, July 23rd. They set an "overweight" rating for the company. Sanford C. Bernstein boosted their target price on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the company a "market perform" rating in a research note on Wednesday, May 13th. Evercore set a $33.00 target price on shares of Dyne Therapeutics in a report on Friday, May 15th. Finally, Wall Street Zen cut shares of Dyne Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 1st. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Dyne Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $34.42.

Dyne Therapeutics Stock Up 1.3%

Shares of NASDAQ:DYN opened at $26.34 on Wednesday. The stock's 50-day moving average price is $23.99 and its two-hundred day moving average price is $19.89. The company has a current ratio of 12.02, a quick ratio of 12.02 and a debt-to-equity ratio of 0.28. Dyne Therapeutics, Inc. has a 12-month low of $11.92 and a 12-month high of $27.31. The firm has a market cap of $4.92 billion, a price-to-earnings ratio of -7.91 and a beta of 1.07.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($1.08) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.33). On average, research analysts forecast that Dyne Therapeutics, Inc. will post -3.47 EPS for the current year.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.

Want to see what other hedge funds are holding DYN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source